{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Morphine+matched+placebo&page=2",
    "query": {
      "intervention": "Morphine matched placebo",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 51,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Morphine+matched+placebo&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Morphine+matched+placebo&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T00:48:34.233Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05571345",
      "title": "A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recreational Drug Use"
      ],
      "interventions": [
        {
          "name": "PF614",
          "type": "DRUG"
        },
        {
          "name": "Oxycodone Hydrochloride 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ensysce Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2022-10-05",
      "completion_date": "2022-12-28",
      "has_results": false,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-10-04T00:48:34.233Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05571345"
    },
    {
      "nct_id": "NCT06406400",
      "title": "Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "AZD4041",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        },
        {
          "name": "Buprenorphine",
          "type": "DRUG"
        },
        {
          "name": "Buprenorphine / Naloxone",
          "type": "DRUG"
        },
        {
          "name": "Hydromorphone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 15,
      "start_date": "2024-05-13",
      "completion_date": "2024-07-31",
      "has_results": false,
      "last_update_posted_date": "2025-03-26",
      "last_synced_at": "2026-10-04T00:48:34.233Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06406400"
    },
    {
      "nct_id": "NCT05147220",
      "title": "Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Remibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1000,
      "start_date": "2021-12-16",
      "completion_date": "2030-10-30",
      "has_results": false,
      "last_update_posted_date": "2026-08-18",
      "last_synced_at": "2026-10-04T00:48:34.233Z",
      "location_count": 52,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05147220"
    },
    {
      "nct_id": "NCT02824276",
      "title": "Sensory Effects of Oral Opioid Treatment in Patients With Chronic Low Back Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Low Back Pain"
      ],
      "interventions": [
        {
          "name": "Oxycodone or morphine sulfate immediate release (MSIR)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Treatment",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "25 Years to 65 Years"
      },
      "enrollment_count": 35,
      "start_date": "2017-01-06",
      "completion_date": "2025-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-10-04T00:48:34.233Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02824276"
    },
    {
      "nct_id": "NCT03657810",
      "title": "A Controlled Study to Determine the Efficacy and Safety of CL-108 5 mg for Acute Pain and the Prevention of OINV",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain",
        "Nausea",
        "Vomiting"
      ],
      "interventions": [
        {
          "name": "CL-108 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Norco",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Charleston Laboratories, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 349,
      "start_date": "2017-08-02",
      "completion_date": "2018-11-30",
      "has_results": true,
      "last_update_posted_date": "2023-03-22",
      "last_synced_at": "2026-10-04T00:48:34.233Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 2 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pasadena",
          "state": "Maryland"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03657810"
    },
    {
      "nct_id": "NCT04586023",
      "title": "Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Fenebrutinib",
          "type": "DRUG"
        },
        {
          "name": "Teriflunomide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 751,
      "start_date": "2021-03-24",
      "completion_date": "2027-07-09",
      "has_results": false,
      "last_update_posted_date": "2026-09-17",
      "last_synced_at": "2026-10-04T00:48:34.233Z",
      "location_count": 12,
      "location_summary": "Cullman, Alabama • Phoenix, Arizona • Torrance, California + 9 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04586023"
    },
    {
      "nct_id": "NCT02600715",
      "title": "Reduction of Bladder Injection Pain With Belladonna Opiate Suppository",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Overactive Bladder",
        "Urinary Urge Incontinence",
        "Urinary Bladder, Neurogenic",
        "Painful Bladder Syndrome"
      ],
      "interventions": [
        {
          "name": "Onabotulinumtoxin A (BoNT)",
          "type": "DRUG"
        },
        {
          "name": "belladonna",
          "type": "DRUG"
        },
        {
          "name": "Morphine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Active B&O suppository of belladonna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Edgar LeClaire, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 26,
      "start_date": "2015-11",
      "completion_date": "2017-06-26",
      "has_results": true,
      "last_update_posted_date": "2018-09-20",
      "last_synced_at": "2026-10-04T00:48:34.233Z",
      "location_count": 2,
      "location_summary": "Wichita, Kansas",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02600715"
    },
    {
      "nct_id": "NCT01585766",
      "title": "Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing Forms"
      ],
      "interventions": [
        {
          "name": "MEDI-551 30 MG-IV",
          "type": "DRUG"
        },
        {
          "name": "MEDI-551 60 MG-SC",
          "type": "DRUG"
        },
        {
          "name": "PLACEBO-IV-SC",
          "type": "DRUG"
        },
        {
          "name": "MEDI-551 100 MG-IV",
          "type": "DRUG"
        },
        {
          "name": "MEDI-551 300 MG-SC",
          "type": "DRUG"
        },
        {
          "name": "MEDI-551 600 MG-IV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 56,
      "start_date": "2012-04-24",
      "completion_date": "2016-06-20",
      "has_results": true,
      "last_update_posted_date": "2018-10-29",
      "last_synced_at": "2026-10-04T00:48:34.233Z",
      "location_count": 9,
      "location_summary": "Scottsdale, Arizona • Long Beach, California • Sacramento, California + 6 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01585766"
    },
    {
      "nct_id": "NCT04032171",
      "title": "Study of Evobrutinib in Participants With RMS",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing-remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Evobrutinib",
          "type": "DRUG"
        },
        {
          "name": "Avonex®",
          "type": "DRUG"
        },
        {
          "name": "Avonex® matched Placebo",
          "type": "DRUG"
        },
        {
          "name": "Evobrutinib matched Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EMD Serono Research & Development Institute, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 1,
      "start_date": "2019-09-10",
      "completion_date": "2020-05-20",
      "has_results": true,
      "last_update_posted_date": "2021-08-05",
      "last_synced_at": "2026-10-04T00:48:34.233Z",
      "location_count": 1,
      "location_summary": "Rockland, Massachusetts",
      "locations": [
        {
          "city": "Rockland",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04032171"
    },
    {
      "nct_id": "NCT05587998",
      "title": "A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Opioid Use Disorder"
      ],
      "interventions": [
        {
          "name": "Morphine",
          "type": "DRUG"
        },
        {
          "name": "AZD4041",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 45,
      "start_date": "2022-08-31",
      "completion_date": "2023-05-25",
      "has_results": true,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-10-04T00:48:34.233Z",
      "location_count": 1,
      "location_summary": "Overland Park, Kansas",
      "locations": [
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05587998"
    }
  ]
}